Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 12, 2021 16:28 ET | Source: Ascendis Pharma

Ascendis Pharma A/S Announces Expansion of Global Clinical Reach for TransCon™ PTH with Filing of the Clinical Trial Notification for Phase 3 Clinical Trial in Adults with Hypoparathyroidism in Japan

COPENHAGEN, Denmark, May 12, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create product candidates...
May 10, 2021 17:17 ET | Source: Ascendis Pharma

Ascendis Pharma A/S Announces Preliminary 58-Week Results from Open-Label Extension of Phase 2 PaTH Forward Trial of TransCon PTH in Adult Hypoparathyroidism Demonstrated Durable Benefit and a Well-Tolerated Safety Profile

– 58 subjects continue in the open-label extension study for TransCon PTH – COPENHAGEN, Denmark, May 10, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company...
May 06, 2021 16:05 ET | Source: Ascendis Pharma

Ascendis Pharma A/S Announces Presentations for TransCon™ PTH at Upcoming Medical Conferences

COPENHAGEN, Denmark, May 06, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical...
May 04, 2021 16:05 ET | Source: Ascendis Pharma

Ascendis Pharma A/S Announces Participation at the BofA Securities 2021 Virtual Health Care Conference

COPENHAGEN, Denmark, May 04, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create product candidates...
April 21, 2021 16:05 ET | Source: Ascendis Pharma

Ascendis Pharma A/S Announces Presentations for TransCon™ hGH at Upcoming Medical Conferences

COPENHAGEN, Denmark, April 21, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical...
March 30, 2021 07:05 ET | Source: Ascendis Pharma

Ascendis Pharma A/S Announces Participation at the J.P. Morgan 10th Annual Napa Valley Biotech Forum

COPENHAGEN, Denmark, March 30, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create product...
March 23, 2021 07:05 ET | Source: Ascendis Pharma

Ascendis Pharma A/S Presents 6-Month Open-Label Extension Data from Phase 2 PaTH Forward Trial of TransCon PTH in Adult Hypoparathyroidism at ENDO 2021

COPENHAGEN, Denmark, March 23, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create product...
March 15, 2021 07:05 ET | Source: Ascendis Pharma

Ascendis Pharma A/S Announces Participation at Oppenheimer 31st Annual Healthcare Conference

COPENHAGEN, Denmark, March 15, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create product...
March 10, 2021 16:01 ET | Source: Ascendis Pharma

Ascendis Pharma A/S Reports Full Year 2020 Financial Results

– Preparations for potential launch of first Endocrinology Rare Disease product candidate, TransCon hGH (lonapegsomatropin), continues on track – – Oncology pipeline advancing into clinical trials...
March 10, 2021 07:05 ET | Source: Ascendis Pharma

Ascendis Pharma A/S Announces Seven Presentations at ENDO 2021, Demonstrating Commitment to People with Rare Endocrine Diseases

COPENHAGEN, Denmark, March 10, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical...